You are here

IMMUNOCHEM THERAPEUTICS LLC

Company Information
Address
105 AUBURN ST
AUBURNDALE, MA 02466-2524
United States



Information

UEI: SCDHKSSUC4T4

# of Employees: 3


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Novel anti-neuroinflammatory drug for aneurysmal subarachnoidhemorrhage (aSAH)

    Amount: $498,363.00

    ABSTRACT Nontraumatic (aneurysmal) subarachnoid hemorrhage (aSAH) is one of the most dangerous forms of stroke, with almost half of victims dying within the first month after diagnosis, and a half of ...

    SBIRPhase I2022Department of Health and Human Services National Institutes of Health
  2. Development of a novel anti-neuroinflammatory experimental therapeutic forepilepsy and Alzheimer's risk

    Amount: $450,367.00

    ABSTRACT Alzheimer’s disease and epilepsy are common age-related CNS disorders. Both Alzheimer’s disease and epilepsy are more frequent in the elderly compared to any other age groups, and a histo ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  3. Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction

    Amount: $1,499,121.00

    PROJECT SUMMARY Cognitive decline and deterioration of long-term cognitive performance are major side effects of CNS cancer treatment. Brain metastases are the most common CNS malignancies and a commo ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  4. Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction

    Amount: $224,888.00

    PROJECT SUMMARY Cognitive decline and deterioration of long term cognitive performance are major side effects of CNS cancer treatmentBrain metastases are the most common CNS malignancies and a common ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  5. First-in-human study of MW151, a novel drug targeting neuroinflammation

    Amount: $1,157,853.00

    ABSTRACT Alzheimerandapos s diseaseADis one of the largest global public health crises facing us todayyet there are no effective therapies available to preventdelayor slow AD progressionDominant appro ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  6. First-in-human study of MW151, a novel drug targeting neuroinflammation

    Amount: $499,320.00

    ABSTRACT Alzheimerandapos s diseaseADis one of the largest global public health crises facing us todayyet there are no effective therapies available to preventdelayor slow AD progressionDominant appro ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government